Table 1. Effects of Specific DAergic and NErgic Drugs on Pyramidal Cell Properties.

Treatment	MP (mV)			IR (MΩ)			Number of spikes/pulse
	Control	Treatment		Control	Treatment		Control	Treatment
Control–MPH (10 μM, n = 30)	72.3 ± 0.2		72.2 ± 0.1	463.3 ± 47.8		435.0 ± 48	3.9 ± 0.3		5.1 ± 0.5*
Control–MPH (1 μM, n = 10)	71.3 ± 0.8		71.2 ± 0.4	359.2 ± 27.2		402.1 ± 37.8	2.8 ± 0.3		2.7 ± 0.6
Control–MPH (reserpine)	70.1 ± 0.6		69.4 ± 0.5				4.0 ± 0.7		4.3 ± 0.9
Control–prazosine–MPH	73.0 ± 0.1	73.5 ± 0.4	72.7 ± 0.2	445 ± 41.2	429.3 ± 40.3	405.4 ± 53.1	2.8 ± 0.2	3.9 ± 0.5	4.9 ± 0.9**
Control–yohimbine–MPH	72.9 ± 1.1	72.2 ± 1.9	72.3 ± 1.2	488.2 ± 82	439.8 ± 59.5	527.4 ± 60	3.4 ± 0.4	3.7 ± 0.5	3.2 ± 0.8
Control–propanolol–MPH	71.8 ± 2.5	71.8 ± 2.1	71.9 ± 2.0	423.4 ± 41.1	267 ± 92.9	420 ± 50.8	4.2 ± 0.8	5.2 ± 1.5	5.1 ± 1.4
Control–SKF 38390–MPH	72.3 ± 0.1	72.6 ± 0.2	71.9 ± 0.2	345.1 ± 64	232 ± 85	327 ± 81.1	3.1 ± 0.3	3.7 ± 0.7	5.4 ± 0.9***
Control–clonidine	71.8 ± 0.4		72.1 ± 0.3	575.3 ± 56.9		418.9 ± 62.7	3.4 ± 0.6		6.1 ± 0.7****

Bold values indicate significant changes.

^*p<0.0007.

^**p<0.01.

^***p<0.03.

^****p<0.000005.